Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | STAT1 | P42224 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | GRM5 | P41594 | 2/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19642451 | 0.88 | AHR (0.56) | ALDH1A1SMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL20477142 | 0.88 | AHR (0.49) | ALDH1A1SMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL19642663 | 0.87 | SMN1; SMN2 (0.54) | ALDH1A1SMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL19642645 | 0.86 | SMN1; SMN2 (0.58) | SMN1; SMN2MAPTNPC1RAB9AKMT2A | |
| SCHEMBL19642664 | 0.86 | SMN1; SMN2 (0.46) | ALDH1A1SMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL20471307 | 0.84 | AHR (0.57) | ALDH1A1SMN1; SMN2MAPTNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL29047232 | 0.83 | AHR (0.56) | ALDH1A1SMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL19660206 | 0.83 | AHR (0.54) | ALDH1A1SMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL19641988 | 0.82 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL19642508 | 0.81 | AHR (0.67) | ALDH1A1SMN1; SMN2MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109863140-B | 3-oxo-2, 6-diphenyl-2, 3-dihydropyridazine-4-carboxamide | 拜耳医药股份有限公司 | 2023-02-21 | — | — | CN | disclosed |
| EP-3464248-B1 | 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | Bayer Pharma AG (DE) | 2021-09-08 | — | — | EP | disclosed |
| EP-3464248-B1 | 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | Bayer Pharma AG (DE) | 2021-09-08 | — | — | EP | disclosed |
| US-11040035-B2 | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-06-22 | — | — | US | disclosed |
| US-11040035-B2 | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-06-22 | — | — | US | disclosed |
| US-20200237757-A1 | 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-07-30 | — | — | US | disclosed |
| US-20200237757-A1 | 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-07-30 | — | — | US | disclosed |
| EP-3464248-A1 | 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | Bayer Pharma Aktiengesellschaft (DE) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017202816-A1 | 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017202816-A1 | 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040035-B2 | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | AHR, HRH2, HRH4 | ALDH1A1 279/4885SMN1; SMN2 4217/4885MAPT 4638/4885 |
| US-20200237757-A1 | 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | AHR, HRH2, HRH4 | ALDH1A1 279/4885SMN1; SMN2 4217/4885MAPT 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.